EUVIMEDEUVIMED entdecken
Crossref

Chitosan-based nanomedicine for metabolic liver diseases: cell-specific targeting, gut-liver axis modulation, and translational perspectives

Paari Ellappan, Sivaa Rajendran, Tamilarasi Selvamurugan

Comparative Clinical Pathology · 21.11.2026 · 35 (1)

DOI: 10.1007/s00580-026-03894-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Comparative Clinical Pathology, online erschienen am 21.11.2026. Verfasst von Paari Ellappan und 2 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Ellappan, P., Rajendran, S., & Selvamurugan, T. (2026). Chitosan-based nanomedicine for metabolic liver diseases: cell-specific targeting, gut-liver axis modulation, and translational perspectives. Comparative Clinical Pathology, 35(1). https://doi.org/10.1007/s00580-026-03894-9

Vancouver

Ellappan P, Rajendran S, Selvamurugan T. Chitosan-based nanomedicine for metabolic liver diseases: cell-specific targeting, gut-liver axis modulation, and translational perspectives. Comparative Clinical Pathology. 2026;35(1). doi:10.1007/s00580-026-03894-9

BibTeX
@article{Ellappan2026,
  author = {Ellappan, Paari and Rajendran, Sivaa and Selvamurugan, Tamilarasi},
  title = {Chitosan-based nanomedicine for metabolic liver diseases: cell-specific targeting, gut-liver axis modulation, and translational perspectives},
  journal = {Comparative Clinical Pathology},
  year = {2026},
  volume = {35},
  number = {1},
  doi = {10.1007/s00580-026-03894-9}
}
Kostenlos starten →